[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.209.104.7. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 2,286
Citations 0
Correction
June 20, 2017

Typographical and Data Errors

JAMA. 2017;317(23):2453. doi:10.1001/jama.2017.7019

In the Original Investigation entitled “Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: the IRONOUT HF Randomized Clinical Trial,”1 published in the May 16, 2017, issue of JAMA, there were typographical errors in the text and errors in the data. In the Primary End Point section of the text, the fourth sentence should read “Between-group differences in change in peak Vo2….” In footnote f of Table 1, the reference range for ferritin should read “100-300 ng/mL.” In the Exploratory End Points section of the text, the level for creatinine should read “(−0.02 mg/dL [−0.09 to 0.05 mg/dL]; P=.65).” In the Iron Bioavailability section of the text, data in the first sentence should be followed by “were all correlated with baseline Tsat levels (18% [IQR, 15% to 22%])” and in the second sentence, the ferritin level should read “(+11.3 ng/mL [−0.3 to 22.9 ng/mL]; P=.06).” In Figure 2 panel C, the y-axis should be labeled “ng/mL.” The IRONOUT HF Trial Members, Investigators, and Committees section should include “Massachusetts General Hospital (laboratory performing hepcidin measurements)—M. Buswell, G. Shelton, K. Allen, D. Bloch.” This article was corrected online.

References
1.
Lewis  GD, Malhotra  R, Hernandez  AF,  et al; NHLBI Heart Failure Clinical Research Network.  Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial.  JAMA. 2017;317(19):1958-1966. doi:10.1001/jama.2017.5427Google ScholarCrossref
×